A 6-year-old boy presents with intense pruritus, lichenified plaques on flexural surfaces (antecubital and popliteal fossae), and a 3-year history of recurrent skin infections. Serum IgE is markedly elevated. His mother reports that emollients alone provide only temporary relief. What is the most appropriate next step in management?

Explanation

## Management Strategy for Moderate-to-Severe Atopic Dermatitis ### Stepwise Approach **Key Point:** The cornerstone of atopic dermatitis (AD) management is a three-pronged strategy: skin barrier repair, anti-inflammatory therapy, and identification/avoidance of triggers. ### Why Topical Corticosteroids + Emollients? 1. **Skin barrier dysfunction** is the primary pathology in AD — impaired filaggrin, reduced ceramides, and increased transepidermal water loss (TEWL). 2. **Emollients** (applied frequently, especially after bathing) restore hydration and reduce TEWL. 3. **Potent topical corticosteroids** (Class II–III, e.g., mometasone furoate, fluticasone propionate) are first-line for active inflammation in a child with lichenification and pruritus. 4. **Systemic corticosteroids** are reserved for acute flares unresponsive to topical therapy or severe generalized disease — not first-line due to rebound flares and long-term adverse effects. ### High-Yield:** In children with moderate AD (lichenified plaques, frequent infections, elevated IgE), the **stepwise approach** is: - Step 1: Emollients + trigger avoidance - Step 2: Topical corticosteroids ± topical calcineurin inhibitors (tacrolimus, pimecrolimus) - Step 3: Phototherapy (narrowband UVB) - Step 4: Systemic agents (dupilumab, azathioprine, cyclosporine) ### Why NOT the Other Options? | Option | Reason | | --- | --- | | Systemic corticosteroids | First-line only in acute severe flares; risk of rebound and HPA axis suppression in children. | | Patch testing | Used to identify contact allergens in suspected allergic contact dermatitis, not primary AD. | | Allergen immunotherapy | No established role in AD management; not recommended as routine therapy. | **Clinical Pearl:** Frequent skin infections in AD are due to impaired barrier function and increased *Staphylococcus aureus* colonization — treat with topical antibiotics (mupirocin) if localized, or short oral antibiotics if systemic signs present. Optimize AD control first to reduce infection risk. [cite:Griffiths 2017 NICE Guidelines; Harrison 21e Ch 325]